| 前收盘价格 | 6.03 |
| 收盘价格 | 1.26 |
| 成交量 | 152,601,536 |
| 平均成交量 (3个月) | 4,927,075 |
| 市值 | 99,456,400 |
| 价格/销量 (P/S) | 204.18 |
| 股市价格/股市净资产 (P/B) | 7.89 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -0.800 |
| 总债务/股东权益 (D/E MRQ) | 17.35% |
| 流动比率 (MRQ) | 7.80 |
| 营业现金流 (OCF TTM) | -62.16 M |
| 杠杆自由现金流 (LFCF TTM) | -37.33 M |
| 资产报酬率 (ROA TTM) | -39.82% |
| 股东权益报酬率 (ROE TTM) | -79.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | aTyr Pharma, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.6
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -3.5 |
| 平均 | 0.63 |
|
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.23% |
| 机构持股比例 | 69.63% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Federated Hermes, Inc. | 30 Jun 2025 | 14,666,600 |
| Integral Health Asset Management, Llc | 30 Jun 2025 | 1,050,000 |
| Point72 Asset Management, L.P. | 30 Jun 2025 | 988,677 |
| Ghost Tree Capital, Llc | 30 Sep 2024 | 800,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 25.00 (Wells Fargo, 2,363.05%) | 购买 |
| 中 | 21.00 (1,968.97%) | |
| 低 | 17.00 (Jefferies, 1,574.88%) | 购买 |
| 平均值 | 21.00 (1,968.97%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 5.29 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Jefferies | 22 Aug 2025 | 17.00 (1,574.88%) | 购买 | 5.35 |
| Wells Fargo | 20 Jun 2025 | 25.00 (2,363.05%) | 购买 | 5.22 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合